Logo image of IBRX

IMMUNITYBIO INC (IBRX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:IBRX - US45256X1037 - Common Stock

2.26 USD
-0.03 (-1.31%)
Last: 12/8/2025, 8:16:59 PM
2.2697 USD
+0.01 (+0.43%)
After Hours: 12/8/2025, 8:16:59 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to IBRX. IBRX was compared to 531 industry peers in the Biotechnology industry. Both the profitability and financial health of IBRX have multiple concerns. IBRX is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year IBRX has reported negative net income.
In the past year IBRX has reported a negative cash flow from operations.
In the past 5 years IBRX always reported negative net income.
In the past 5 years IBRX always reported negative operating cash flow.
IBRX Yearly Net Income VS EBIT VS OCF VS FCFIBRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M -400M -500M

1.2 Ratios

Looking at the Return On Assets, with a value of -67.17%, IBRX is doing worse than 61.39% of the companies in the same industry.
Industry RankSector Rank
ROA -67.17%
ROE N/A
ROIC N/A
ROA(3y)-112.85%
ROA(5y)-102.54%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IBRX Yearly ROA, ROE, ROICIBRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100

1.3 Margins

With an excellent Gross Margin value of 99.55%, IBRX belongs to the best of the industry, outperforming 98.87% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for IBRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 99.55%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IBRX Yearly Profit, Operating, Gross MarginsIBRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100K -200K -300K

More info and screens

3

2. Health

2.1 Basic Checks

IBRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
IBRX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for IBRX has been increased compared to 5 years ago.
Compared to 1 year ago, IBRX has a worse debt to assets ratio.
IBRX Yearly Shares OutstandingIBRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M
IBRX Yearly Total Debt VS Total AssetsIBRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

Based on the Altman-Z score of -9.46, we must say that IBRX is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -9.46, IBRX is doing worse than 72.32% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -9.46
ROIC/WACCN/A
WACC9.63%
IBRX Yearly LT Debt VS Equity VS FCFIBRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M

2.3 Liquidity

A Current Ratio of 5.77 indicates that IBRX has no problem at all paying its short term obligations.
IBRX has a Current ratio (5.77) which is comparable to the rest of the industry.
IBRX has a Quick Ratio of 5.65. This indicates that IBRX is financially healthy and has no problem in meeting its short term obligations.
IBRX has a Quick ratio of 5.65. This is in the better half of the industry: IBRX outperforms 60.26% of its industry peers.
Industry RankSector Rank
Current Ratio 5.77
Quick Ratio 5.65
IBRX Yearly Current Assets VS Current LiabilitesIBRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

8

3. Growth

3.1 Past

IBRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 52.87%, which is quite impressive.
Looking at the last year, IBRX shows a very strong growth in Revenue. The Revenue has grown by 1025.95%.
Measured over the past years, IBRX shows a very strong growth in Revenue. The Revenue has been growing by 46.30% on average per year.
EPS 1Y (TTM)52.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.67%
Revenue 1Y (TTM)1025.95%
Revenue growth 3Y151.22%
Revenue growth 5Y46.3%
Sales Q2Q%425.07%

3.2 Future

The Earnings Per Share is expected to grow by 29.95% on average over the next years. This is a very strong growth
IBRX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 161.08% yearly.
EPS Next Y24.42%
EPS Next 2Y20.34%
EPS Next 3Y24.81%
EPS Next 5Y29.95%
Revenue Next Year639.35%
Revenue Next 2Y273.14%
Revenue Next 3Y232.26%
Revenue Next 5Y161.08%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
IBRX Yearly Revenue VS EstimatesIBRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2B 4B 6B
IBRX Yearly EPS VS EstimatesIBRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IBRX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IBRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IBRX Price Earnings VS Forward Price EarningsIBRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IBRX Per share dataIBRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4

4.3 Compensation for Growth

A more expensive valuation may be justified as IBRX's earnings are expected to grow with 24.81% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.34%
EPS Next 3Y24.81%

More info and screens

0

5. Dividend

5.1 Amount

IBRX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IMMUNITYBIO INC

NASDAQ:IBRX (12/8/2025, 8:16:59 PM)

After market: 2.2697 +0.01 (+0.43%)

2.26

-0.03 (-1.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04 2025-11-04/amc
Earnings (Next)03-02 2026-03-02/amc
Inst Owners14.83%
Inst Owner Change15.2%
Ins Owners3.43%
Ins Owner Change0%
Market Cap2.23B
Revenue(TTM)82.56M
Net Income(TTM)-348.62M
Analysts85.45
Price Target10.4 (360.18%)
Short Float %24.51%
Short Ratio8.61
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)23.66%
Min EPS beat(2)10.87%
Max EPS beat(2)36.46%
EPS beat(4)3
Avg EPS beat(4)22.08%
Min EPS beat(4)-14.89%
Max EPS beat(4)55.88%
EPS beat(8)4
Avg EPS beat(8)-0.69%
EPS beat(12)6
Avg EPS beat(12)-2.54%
EPS beat(16)7
Avg EPS beat(16)-4.44%
Revenue beat(2)1
Avg Revenue beat(2)6.19%
Min Revenue beat(2)-1.41%
Max Revenue beat(2)13.79%
Revenue beat(4)2
Avg Revenue beat(4)2.05%
Min Revenue beat(4)-5.28%
Max Revenue beat(4)13.79%
Revenue beat(8)5
Avg Revenue beat(8)69.43%
Revenue beat(12)9
Avg Revenue beat(12)193.68%
Revenue beat(16)12
Avg Revenue beat(16)257.51%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)10.53%
EPS NY rev (1m)12.23%
EPS NY rev (3m)12.23%
Revenue NQ rev (1m)1.69%
Revenue NQ rev (3m)2.04%
Revenue NY rev (1m)5.1%
Revenue NY rev (3m)5.1%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 26.96
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.41
EYN/A
EPS(NY)-0.34
Fwd EYN/A
FCF(TTM)-0.33
FCFYN/A
OCF(TTM)-0.32
OCFYN/A
SpS0.08
BVpS-0.53
TBVpS-0.55
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -67.17%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 99.55%
FCFM N/A
ROA(3y)-112.85%
ROA(5y)-102.54%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.16
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 32.21%
Cap/Sales 6.16%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.77
Quick Ratio 5.65
Altman-Z -9.46
F-Score6
WACC9.63%
ROIC/WACCN/A
Cap/Depr(3y)249.59%
Cap/Depr(5y)199.51%
Cap/Sales(3y)15458.8%
Cap/Sales(5y)10051.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.67%
EPS Next Y24.42%
EPS Next 2Y20.34%
EPS Next 3Y24.81%
EPS Next 5Y29.95%
Revenue 1Y (TTM)1025.95%
Revenue growth 3Y151.22%
Revenue growth 5Y46.3%
Sales Q2Q%425.07%
Revenue Next Year639.35%
Revenue Next 2Y273.14%
Revenue Next 3Y232.26%
Revenue Next 5Y161.08%
EBIT growth 1Y27.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y15.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6.58%
OCF growth 3YN/A
OCF growth 5YN/A

IMMUNITYBIO INC / IBRX FAQ

Can you provide the ChartMill fundamental rating for IMMUNITYBIO INC?

ChartMill assigns a fundamental rating of 3 / 10 to IBRX.


What is the valuation status for IBRX stock?

ChartMill assigns a valuation rating of 1 / 10 to IMMUNITYBIO INC (IBRX). This can be considered as Overvalued.


What is the profitability of IBRX stock?

IMMUNITYBIO INC (IBRX) has a profitability rating of 1 / 10.


What is the financial health of IMMUNITYBIO INC (IBRX) stock?

The financial health rating of IMMUNITYBIO INC (IBRX) is 3 / 10.


What is the expected EPS growth for IMMUNITYBIO INC (IBRX) stock?

The Earnings per Share (EPS) of IMMUNITYBIO INC (IBRX) is expected to grow by 24.42% in the next year.